search icon
      blog search icon

      What Caused Autolus Therapeutics (AUTL) Stock to Rise Nearly 15%? - Stocks Telegraph

      By Fahim Awan

      Published on

      August 2, 2021

      1:16 PM UTC

      What Caused Autolus Therapeutics (AUTL) Stock to Rise Nearly 15%? - Stocks Telegraph

      The shares of Autolus Therapeutics plc (AUTL) were up 14.29% at $6.08 in premarket trading Monday. AUTL stock dropped -0.19% to end last trading session at $5.32. A total of 0.34 million shares were traded on AUTL, which is below the daily average of 1.74 million shares traders have been trading for the last 50 days.

      Within the last five days, AUTL stock has declined -3.62%; however, over the last month, it has fallen -19.88%. Over the last three months, the price of AUTL stock has dropped -8.59%, and it has dropped -40.49 percent so far this year. A Moderna agreement has resulted in an increase in AUTL stock price.

      What is the purpose of AUTL’s partnership?

      Biopharmaceutical company Autolus develops next-generation cancer therapies using programmed T cells. AUTL develops tailored, controlled, and highly active T cell therapies to improve cancer recognition, eliminate cancer cells, and break down cancer cells’ defense mechanisms using a broad variety of proprietary technologies and modules. AUTL is developing product candidates to treat hematological and solid tumor cancers.

      Autolus today announced an agreement with Moderna, a company developing messenger RNA (mRNA) therapeutics and vaccines, granting Moderna an exclusive license to introduce mRNA therapeutics throughout the world that incorporate Autolus’s proprietary binders.

      • For each licensed target, AUTL is eligible to receive an upfront payment from Moderna and for each commercially successful product, AUTL could receive a milestone payment.
      • As part of the agreement, AUTL would receive royalty payments on all products it commercializes.
      • Autolus and Moderna have formed a partnership to develop mRNA-based therapeutics for oncology indications.
      • Autolus’ leadership in innovation and differentiation in the binder and cell programming technology is reflected in the use of AUTL’s technology in Moderna’s mRNA platform.
      • As AUTL’s CEO, Christian Itin recently took part in a panel discussion titled “Cell Therapies In the Next Decade”, which took place virtually from July 14-15, 2021 at the William Blair Biotech Focus Conference 2021.
      • The AUTL conference also featured virtual one-on-one meetings with experts. The panel discussion is available on AUTL’s website for 30 days.

      AUTL Stock is set to release quarterly results:

      Before the opening of the U.S. markets on Thursday, August 5, 2021, Autolus Therapeutics (AUTL) will announce its financial results and operational highlights for the second quarter of 2021. A conference call and webcast will be conducted by AUTL’s management at 8:30 am EST/12:30 pm GMT to discuss the company’s financial results. The webcast and accompanying slide presentations can be found on AUTL’s website in the events section.

      More From Stocks telegraph